Answers are grounded in this paper and cite their sources.
BACKGROUND: A study of a large cohort, including early-onset or familial patients with Parkinson's disease (PD), has deciphered the contribution of known PD genes. However, many other genes, thereafter labeled parkinsonism-associated genes (PAG), are associated with other neurological conditions in which parkinsonism is sometimes reported. OBJECTIVE: The aim was to evaluate the contribution of these genes in patients with predominant parkinsonism. METHODS: We performed whole-exome sequencing in a cohort of 1488 probands with early-onset (here defined by an age at onset <45) or familial predominant parkinsonism (1756 in total) who did not have a pathogenic variant in seven known PD genes (GBA1, LRRK2, PARK7, PINK1, PRKN, SNCA, VPS35). One hundred eighteen PAGs were selected for the analysis based on their assessment by experts in three different consortia (Genomics England PanelApp, PanelApp Australia, International Genetic Nomenclature in Movement Disorders Study Group). Pathogenic variants were extracted from these genes according to the criteria of the American College of Medical Genetics. RESULTS: Eighty-one probands (5.4%) carried a pathogenic variant of one PAG. Clinical review (available for 71/81 probands) revealed that the phenotype was compatible with the variant in 91.5% (65/71) of probands. Thirty-seven genes were considered disease causing. Among them, six (ATP13A2, ATXN2, FIG4, GCH1, PLA2G6, PPP2R5D) accounted for a large proportion of probands with a compatible phenotype (26/65, 40.0%). CONCLUSIONS: Our results indicate that PAGs would account for about 5% of patients with early-onset or familial predominant parkinsonism not mutated for known PD genes, and that clinical evaluation is essential to establish causality.
No takes yet. Share an insight, caveat, or question.
Rousvoal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: